Compare Main Street Capital Corporation (MAIN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Sana Biotechnology Inc — how do they compare? Main Street Capital Corporation trades at $58.65 (market cap $5.52B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Main Street Capital Corporation is far larger — about 4.9× Sana Biotechnology Inc's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MAIN | SANA | |
|---|---|---|
Market Cap | $5.52B | $1.13B |
Sector | Financials | Health |
52-Week High | $67.54 | $5.92 |
52-Week Low | $49.63 | $2.68 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $59.10, up 0.99% with a bullish technical outlook. The stock shows strong fundamentals with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings missed estimates. Recent news highlights MAIN's dividend reliability amid sector challenges, with the company maintaining payouts while peers face cuts. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $59-60.
MAIN offers stable income with consistent dividends but faces headwinds from declining revenue projections ($592M in 2025 to $559M in 2026). Analyst consensus is cautious with 78.57% hold ratings and a $56.67 price target below current levels. Key risks include BDC sector pressure and expense growth impacting earnings coverage.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
